The U.S. FDA has approved Cobenfy capsules for treating schizophrenia in adults. This drug is notable as it is the first antipsychotic to target cholinergic receptors instead of the traditional dopamine receptors. Cobenfy aims to provide a new treatment option for patients who may not respond well to existing medications or suffer from significant side effects, representing a significant advancement in the management of schizophrenia.